Selected Insights

Overview What are Structured Products? Investing in Structured Products Terminology History of Structured Products Selected Insights FAQs about Structured Products

Below are thought leadership pieces focused on structured products. These accounts provide insights from experts who have played a pivotal role in the field.

Decrement indices and autocallable structures: the good, the bad and the ugly

This article looks at how these indices are built, how they differ from real indices and the potential consequences for the investors and for the banks.

29 Nov 2021 by Eric Barthe
Insight bricks from data clay

“Data! Data! Data!" cried Sherlock Holmes.

02 Nov 2021 by SRP News
Market neutral: playing vol and correlation

Within the funds world there are many interesting strategies used by managers to provide diversification or outperformance over the mainstream funds in the traditional asset classes.

01 Sep 2021 by Tim Mortimer, FVC
Citi takes portfolio management and QIS to the next level

Citi’s multi-asset active allocation solution, developed in partnership with BlackRock as allocation provider and distributed so far in Asia via a third party private bank and retail aggregator, is gaining traction as demand for QIS and active management increases.

06 May 2021 by Citi - Sponsored Content
Industry has shown resilience, now it is at an inflection point

Over the last few years, the structured product industry has responded well to regulatory and transformational change.

29 Apr 2021 by David Wood - Luma Financial Technologies
Pharma in structured products (part 5) - option trading strategies and delta hedging

The next section of our analysis focuses on call butterfly, iron condor, bull call spread and bear put Spread option strategies and how adequately their profit potential has been realised in the case of Teva Pharmaceutical (Teva), BioMarin Pharmaceutical (BMRN), HCA Healthcare (HCA), Merck (MRK), and Fresenius Medical Care (FMS).

26 Mar 2021 by Filip Dyankov
Pharma in structured products (part 4) – technical analysis of pharmaceutical stocks

In this article we apply the Donchian Channel on a sample of 16 stocks – Amgen, Bayer, Biogen, BioNTech, CSPC Pharmaceutical Group, CVS Health, Exact Sciences, Fresenius, Gilead Sciences, Merck, Moderna, Pfizer, Sanofi, Teladoc Health, UnitedHealth, and Vertex Pharmaceutical), as well as the Chakin Moneyflow Index and Aroon Up/Down indicator on a set of five securities.

25 Mar 2021 by Filip Dyankov
Pharma in structured products (part 3) – performance and underlying analysis

In the third part of our analysis, we look at the markets that saw the best performance for pharma products during 2020 as well as modern portfolio theory (MPT) considerations and its deficiencies when applied to the structured product ecosystem.

24 Mar 2021 by Filip Dyankov
Pharma in structured products (part 2) - stagnating issuance in main pharma markets

Buoyant issuance in Malaysia, Belgium and France; reverse convertibles linked to pharma companies have been less affected than growth products, notably the leverage long with stop loss; US breakdown – CVS Health losing ground in sales, Merck records sustained growth.

23 Mar 2021 by Filip Dyankov

Interested in how structured products intelligence can power your business?

Request Demo
Who we are

Launched in 2003, SRP is the leading provider of intelligence for the global structured product market, trusted by investment banks, hedge funds, product issuers and distributors, exchanges and asset managers.

Today, we enable market players to find any product from over 40 million in our database and easily analyse the market. Our news service and global events cover the latest insights into the structured products market and recognises industry leading talent through our awards programmes.

Learn more
Image
( History of Structured ProductsPrev FAQs about Structured ProductsNext )